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Development and pilot testing of an
adaptable protocol to address postpartum
depression in pediatric practices serving
lower-income and racial/ethnic minority
families: contextual considerations
Sarah L. Goff1,2* , Michael J. Moran2, Kathleen Szegda3, Tina Fioroni4, Mary Ann DeBanate3 and Nancy Byatt5,6,7
Abstract
Background: Postpartum depression (PPD) affects approximately 25% of women in lower-income and racial/ethnic
minority populations in the USA. Evidence-based interventions for PPD screening and treatment exist, but many women
with PPD are not identified or are inadequately treated. To address this gap, the American Academy of Pediatrics
recommends screening for PPD at routine preventive visits in the first 6 months of postpartum, but less than half of
pediatricians do so. Small PPD screening studies have been conducted in pediatric practices serving average-risk women,
but less is known about practices serving families with lower-income and/or racial/ethnic minority status (safety-net
practices). Study objectives were (1) to develop and pilot test an adaptable PPD screening protocol in safety-net practices
and (2) to test strategies for implementing the protocol.
Methods: The Consolidated Framework for Implementation Research was used for this two-phase pilot study. Phase I
focus groups with pediatric providers and staff in four safety-net practices informed phase II development and
implementation of a PPD screening and referral protocol. Feasibility measures included the percentage of eligible women
screened and documentation of follow-up plans in the electronic health record at 1-, 2-, 4-, and 6-month preventive visits
over 3 months. Implementation strategies were assessed for acceptability, appropriateness, and feasibility.
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Results: Focus group participants felt that (1) addressing PPD in the pediatric setting is important, (2) all clinical team
members should be engaged in screening, (3) workflows and competing interests may present barriers, and (4)
commonly used screening tools/approaches may not adequately detect depression in the population studied. During
protocol implementation, screening rates increased from 75 to 85% for 324 eligible preventive visits and documentation
of follow-up plans increased from 66 to 87%. Only 6.5% of women screened positive (EPDS ≥ 10). Minor adaptations to
implementation strategies were recommended to improve acceptability, appropriateness, and feasibility.
Conclusions: Although developing and implementing an adaptable protocol for PPD screening in safety-net pediatric
practices using external facilitation and a bundle of implementation strategies appear feasible, low positive screen rates
suggest adaptations to account for intersecting patient, practice, and external policy contexts are needed to improve PPD
screening effectiveness in these practices.
Keywords: Postpartum depression, Screening, Pediatric practice, Implementation, Context, Disparities
Introduction
One in seven women overall and as many as one in four
women in lower-income and racial/ethnic minority popula-
tions in the USA develop postpartum depression (PPD), also
known as postnatal depression, in the year following the
birth of a child [1–4]. While other factors, such as prior de-
pression or being a mother of multiples, also increase risk
for PPD, this study focuses on women with lower-income
and racial/ethnic minority status because of the health dis-
parities experienced by these populations in the USA. The
US Preventive Services Task Force, the American College of
Obstetricians and Gynecologists, and the American Acad-
emy of Pediatrics recommend universal screening for PPD
across maternal and child healthcare settings [5–7].
Evidence-based practices for PPD screening and treatment
exist [8–11], but the vast majority of women go undiag-
nosed or are inadequately treated [12]. The consequences of
untreated PPD include impaired relationships, diminished
social function, higher rates of suicide and infanticide, and
lost work days [13]. PPD also has long-lasting negative im-
pacts on child development [14]. Barriers to effective
screening and referral for treatment have been described at
the patient (e.g., stigma, trauma, language, literacy) [15],
provider (e.g., inadequate training) [7], and system (e.g.,
work-flow, mental health referrals, insurance) levels [10, 16,
17]. Some barriers may have a greater impact on popula-
tions that experience health disparities.
Infants are seen by a pediatric provider (physician or ad-
vance practitioner (AP)) for routine preventive care seven
or more times in the first 12months of life, presenting nu-
merous opportunities for PPD screening [18]. However,
fewer than half of pediatric providers routinely screen for
PPD [7]. Strategies to improve PPD screening and referral
in the pediatric setting have been tested in small US-based
quality improvement studies [19–22], but the studies have
taken place primarily in practices serving average-risk
populations and have focused on changes in screening
rates alone. This study’s overall aim was to develop and
pilot test an intervention to improve PPD screening and
referral in pediatric practices that serve predominantly
lower-income and racial/ethnic minority families (safety-
net practices—referred to as “practices” throughout the
manuscript). This manuscript focuses on the screening as-
pects of the study. Referral will be reported elsewhere so
that the complexities of identifying and addressing chal-
lenges to implementing both screening and referral can be
fully described and the implications for research and clin-
ical care can be fully explicated for each as well.
Methods
Overview
The objectives of this two-phase study were (1) to de-
velop and pilot test an adaptable PPD screening protocol
Contributions to the literature
 Pediatric healthcare providers in practices serving families
with lower-income and racial/ethnic minority status in the
USA agreed that screening mothers for postpartum depres-
sion (PPD) at preventive health visits for 1- to 6-month-old
infants is important, but also had concerns that commonly
used screening instruments and processes may fail to iden-
tify women with PPD in their practice settings.
 Facilitated development and implementation of a PPD
screening and referral protocol tailored to a pediatric
practice’s needs may overcome some barriers to PPD
screening in pediatric practices serving families with lower-
income and racial/ethnic minority status.
 The lower-than-expected percentage of women with posi-
tive screens for PPD found in this study (6.5% vs 25%) sug-
gests that efforts to improve PPD screening in pediatric
practices serving families with lower-income and racial/eth-
nic minority status may require adaptations to both the
screening tool and strategies to implement it to account for
contextual factors.
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for safety-net practices and (2) to pilot test a bundle of
strategies for implementing the protocol. In phase I, for-
mative focus groups were conducted at four safety-net
practices. In phase II, focus group data were used to de-
velop a protocol for PPD screening and pilot test the
protocol and a bundle of strategies to implement the
protocol. The study was approved by the University of
Massachusetts Medical School-Baystate Institutional Re-
view Board. The Consolidated Framework for Imple-
mentation Research (CFIR) [23] served as the conceptual
and analytic framework for this mixed-methods pilot
study. CFIR was selected because its five domains (inter-
vention characteristics, outer setting, inner setting, char-
acteristics of individuals, and process of implementation)
are pertinent to the implementation of complex inter-
ventions such as screening for PPD in safety-net prac-
tices, and its flexible structure is designed to be used
across all phases of the study (Fig. 1). An advisory board
was convened for the study so that the perspectives of
stakeholders outside of the healthcare system could be
included. The board included the director for research
and evaluation of a community-based public health
organization, a behavioral health administrator, and the
leader of a county-wide perinatal depression coalition.
The Board met with the lead investigators (SG and NB)
via telephone twice monthly to provide input on design,
review study materials, and help interpret data.
Phase I: Focus groups
Sampling and recruitment
Safety-net practices (referred to as “practices” through-
out the manuscript) located in the county in which the
study was conducted were purposively sampled to in-
clude practice characteristics that could potentially facili-
tate or hinder efforts to implement a PPD screening
protocol, such as practice size, presence of a co-located
Fig. 1 Integration of CFIR across stages of the study
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behavioral health team, and organizational structure
(e.g., large integrated health care system, managed care
organization). An e-mail was sent to practice leaders in-
viting their practice to participate; the study was then
explained further by phone and a time for the focus
group scheduled if indicated.
Focus group procedures and analysis
Focus groups were conducted using a semi-structured
interview guide that was pre-tested with the Advisory
Board. Interview questions explored topics related to all five
CFIR domains (Fig. 1) [15, 23]. Interview questions aimed
to understand current approaches to PPD screening and re-
ferral, identify perceived barriers and facilitators to effective
PPD screening and referral, and elicit recommendations for
best approaches to developing and implementing PPD pro-
tocols in this setting. Focus groups took place at practice
sites, lasted approximately 1 h, and were facilitated by the
study’s lead investigator, a physician-investigator experi-
enced in using qualitative methods. A trained research as-
sistant (MM) took field notes [24], and the sessions were
audiotaped and professionally transcribed.
Data were analyzed using qualitative content analysis, a
method commonly used when there is existing knowledge
about a phenomenon [25]. An a priori codebook was cre-
ated using the five CFIR domains [23]. SG and MM ap-
plied codes (labels to categorize small portions of the text)
to transcripts iteratively, adding new codes when indi-
cated. Codes were then sorted into major themes (groups
of codes that describe a broader phenomenon) and sub-
themes; the analysis was supported by the Dedoose ana-
lytic software [26]. Data saturation was achieved as evi-
denced by no new themes emerging in the final two focus
groups. Major themes were compared to prior studies of
PPD screening in the pediatric setting to ascertain support
for concepts previously identified and to identify new
concepts.
Phase II: Protocol development and pilot testing of
protocol and implementation strategies
One of the phase I practices was selected to serve as the
phase II test site based on its organizational complexity
(urban pediatric residency program), readiness for im-
plementation based on its engagement in phase I, and
interest in developing and implementing a PPD protocol.
The test site had 11 general pediatric providers and 27
pediatric residents; more than 90% of its patients were
insured by Medicaid (state-sponsored insurance for
lower-income families); the majority of patients were
African-American or Hispanic and spoke a primary lan-
guage other than English. Potential facilitators and bar-
riers to implementing evidence-based PPD screening
identified within CFIR domains in phase 1 informed
protocol development and implementation (Fig. 1).
Twelve implementation strategies, drawn from the Ex-
pert Recommendations on Implementing Change [27],
were tested as a bundle in the study. The strategies,
listed in Table 1 and numbered in parentheses in the
text, were selected through an iterative process that in-
cluded the investigators, the Advisory Board, and the
multi-disciplinary PPD workgroup convened at the test
site for the study (#1). The workgroup included a
pediatric provider “champion” (#2), a front desk staff
member, a nurse, a behavioral health clinician, and a com-
munity health worker. The group met twice monthly for
the duration of the study, and meetings were facilitated
(#3) by members of the investigative team.
Screening protocol development
The workgroup members first decided on the desired
outcomes for the newly implemented PPD screening
protocol. During this process, they discovered that a
PPD protocol had been developed in the practice several
years previously but was not being used. The prior
protocol included guidelines for when to screen mothers
and recommended actions based on screening results.
The workgroup felt the prior protocol had too little in-
formation, was difficult to interpret, had outdated infor-
mation, and had not been implemented well. They
decided to revise the existing protocol, taking barriers
and recommendations from phase I focus groups into
account and addressing additional potential barriers
identified during workgroup planning meetings using
CFIR as a guide (Fig. 1). The workgroup developed and
delivered educational and informational sessions to the
pediatric providers, residents, and staff in the practice
that included efforts to address barriers. These sessions
also aimed to gather input, identify additional perceived
barriers and facilitators, and build consensus on the
need for and approach to revising and implementing the
Table 1 Implemantation strategies included in the strategy
bundle bundle
Implementation strategies
1. Assess for readiness and identify barriers and facilitators
2. Audit and provide feedback
3. Conduct educational meetings
4. Conduct local consensus discussions
5. Conduct local needs assessment
6. Facilitation
7. Identify and prepare champions
8. Use advisory boards and workgroups
9. Tailor strategies
10. Remind clinicians
11. Involve patients/consumers and family members
12. Use train-the-trainer strategies
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PPD protocol (#4, #5, #6, #7). In addition, the practice’s Pa-
tient and Family Advisory Council was consulted to obtain
patient perspectives (#8). Prior to the study, the practice
screened mothers for PPD using the Edinburgh Postnatal De-
pression Scale (EPDS) [28] as part of a developmental screen-
ing packet and continued using this instrument during the
study. Sensitivity and specificity of the 10-item EPDS vary de-
pending on the population screened; however, a cutoff score
of 10 (out of 30) is generally considered sufficiently sensitive
and specific to indicate a high likelihood of PPD [29].
Development and Pilot-testing of Implementation Strategies
In addition to the strategies used during protocol develop-
ment, the workgroup tailored their selection of implementa-
tion strategies to their practice’s needs (#9) and included
texting providers bi-weekly with individual reports on screen-
ing performance (#10), creating a PPD toolkit that included
the protocol and community resources and placing it in each
exam room as a reminder for providers (#10), and providing
mothers a brief written rationale for screening on the cover
of the screening tool (#11). The facilitators provided add-
itional training for workgroup members to support them in
training others in the practice to use the protocol (#12).
Measures
Measures to assess uptake of the protocol included a re-
view of the practice’s electronic health record (EHR) to
determine whether a completed EPDS form (screening
tool) was present, the pediatric provider documented that
the screening results had been reviewed, and a follow-up
plan was documented for women with positive screens.
These data were extracted for all preventive care visits for
1-, 2-, 4-, and 6-month-old infants that occurred at the
test site between May 1 and June 30, 2018 (pre-implemen-
tation), and October 1 through December 31, 2018 (im-
plementation). The percentage of EPDS scores that were
10 or higher (high likelihood of PPD) was also calculated.
Measures to evaluate the implementation strategy bundle
included acceptability, appropriateness, and feasibility [30]
and were assessed: by eliciting and documenting real-time
feedback on the implementation strategies and process
from providers and staff verbally during standing practice
meetings and via e-mail, and by observations made by the
facilitators and workgroup over the course of the study.
Results
Phase I: Focus groups
Focus groups were conducted with a total of 28 pediatric
providers and staff at four of the five practices invited to
participate. The practices ranged in size from four to 38
providers (including residents); three were part of a large
integrated health system and one was a multi-site, multi-
specialty practice. Additional practice and provider data
are located in Table 2.
Potential facilitators and barriers to implementing
evidence-based PPD screening in practices serving fam-
ilies with lower-income and racial/ethnic minority status
were identified in the following CFIR domains: (1) inter-
vention characteristics, (2) inner setting, (3) outer set-
ting, and (4) processes. Linkages between these findings
and protocol development and implementation are
depicted in Fig. 1. Selected sub-themes for these do-
mains are described below with illustrative quotes; add-
itional sub-themes and quotes are located in Table 3.
Intervention characteristics—screening tools
Although participants felt that it was important for
pediatric practices to screen mothers for PPD, many also
felt that commonly used screening instruments such as
the EPDS [28] might not accurately identify women at risk
for PPD in lower-income and racial and ethnic minority
populations. Some felt that cultural factors and low liter-
acy levels might make screening instruments hard for
some women to complete, “I don’t know if the depression
questions often resonate … like if there’s cultural differ-
ences with how they’re interpreted or it’s a literacy thing.”
Several participants also thought that mothers might be
afraid that disclosing depressive symptoms would risk
drawing the attention of child protection services. Many
felt that verbal screening might be more effective and that
Table 2 Focus group participant demographics
Participant characteristics (N = 28) N (%)










Nurse practitioner 4 (14)
Community health worker 2 (7)
Certified nurse-midwife 2 (7)
Resident physician 2 (7)
Behavioral health clinician 1 (4)
Medical assistant 1 (4)
Physician’s assistant 1 (4)
Registered nurse 1 (4)
Schedule coordinator 1 (4)
Years in profession/position, mean (range) 14 (1 month–35 years)
Years at practice, mean (range) 9 (1 month–31 years)
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having a prior positive connection with a mother likely in-
creased comfort with the disclosure of depressive
symptoms.
Inner setting—a team responsibility
Participants almost unanimously felt that screening would be
most effective if the entire clinical team was involved, “I think
it is everyone [on the clinical team who is responsible for
screening]. It starts from the get-go when they come in,
through the MAs [medical assistants] and then, if you notice
something, you relay that on to the provider.” Some partici-
pants felt that the front desk staff were more likely than the
pediatric provider to see that a mother is stressed or having
difficulty and may have more insight into her life situation be-
cause they are from the same community. They also felt that
the front desk staff may more easily gain the trust of patients.
Table 3 Major themes and sub-themes with illustrative quotes
CFIR domain and sub-theme Quotes
1. Intervention
Appropriateness of pediatric providers
screening for PPD
“In the pediatric world, you get your patient, you get their family, you get the constellation.”
“The health of the mother affects the health of the child.”
“For pediatrician as that piece…we have like twice the number of opportunities to screen.”
Perception of mothers’ reactions to
screening
“I think if you have a rapport with a family, it is so much better…I do think people open up
more readily if I know the mom and the other children… you can even sense it more than
someone you don’t know.”
“Sometimes they’re a little confused because they don’t expect us to ask that, because they think that
we’re here to provide care for the baby.”
“I think by the sixth-month visit, sometimes they’ve gone, why are you asking me?”
Screening tools “… are there different questions we should be asking them based on cultural identify that might be
more specific to them in how they are experiencing postpartum depression… just wondering how many
we are missing based on the way we are asking the questions…”
“You are asking her a whole bunch of questions. You can see that she is exhausted, you can see that she
is stressed, and you do reflective questioning…You get a sense, outside of those questions, then, when
you are dealing with them on a human level and you are really responding to where they are at, they
are more likely to say, ‘Yes, I would talk to somebody about that. Yes, I could need some help with that’.”
2. Inner setting
Practice size “It is just hard to do in our setting. I do think people open up more readily if I know the mom and the
other children.”
Electronic medical record (EMR) “If they’re in our system, we can easily send a letter, you know, a quick note over to the OB and say can
you please get this one in, but when they’re not part of [our system] is when it becomes a nightmare.”
“… if we expanded pediatrics to perinatal and OB into the baby… We[could] sign a release, the mom
signs off a release, and offices talk. When they score on a peri-birth and it is positive, that goes in the
baby’s chart.”
Team responsibility “We are still in a silo mode of ‘this is OB and this is pediatrics’. I think we are crossing into that idea that
we are going to get more involved with the women’s clinic... and more involved in the prenatal care…”
Internal linkages to behavioral health “They [behavioral health clinicians in the system] pretty much only see private patients, so…we rarely use
our own mental [health services]…”
3. Outer setting
Behavioral health resources “It’s helpful [to have co-located behavioral health care], but so I just wonder, how the other end of [the
service] works, I don’t know.”
“I think we would feel better if we could call [the service] ourselves…[We] get the sense that nothing’s
going to really happen. You already have a therapist, but apparently…it has to be their provider who
calls. They’ve made that quite clear.”
“They just send us this list of some names and phone numbers, but sometimes even with that list, our
patients have a lot of trouble and people don’t return their calls.”
[the pediatrician] “…can’t make the referral because the mother’s not [their] patient.”
Privacy laws [pediatric providers ]“… have no idea at all what is going on…[with a mother’s healthcare across the
health system]… [information relating to mothers is] an important piece [of caring for their children]”
4. Processes
Positive screens “I am worried if I get a positive [screen], what to do next.”
“[With behavioral health services] you get advice…but you don’t always know when somebody’s going
where. And you don’t get, you often – you may get that immediate [response], but after that it’s still a
black hole.”
Preventive care visit priorities “I have to remember [to screen] and if the visit gets complicated it may not be something that crosses
my mind until they have left the room and I realize we didn’t check it.”
“Sometimes it [depression symptoms] comes up at the very end [of a visit] and we’re behind and it
becomes challenging to address.”
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Outer setting—privacy laws
Many participants felt that privacy laws presented bar-
riers to identifying women at risk for PPD because the
laws inhibit the exchange of patient information between
pediatricians and women’s healthcare providers, “I think
probably one of the biggest barriers is HIPAA and cross-
ing the barrier between ‘Mom is not my patient’ which…
from a provider standpoint is stupid because the mom
and the baby are linked…so, the fact that something… is
[affecting] the baby because of mom [but I can’t] reach
out to mom doesn’t make a lot of sense.”
Processes—preventive care visit priorities
Several participants commented that they felt that PPD
screening was not currently a high priority during pre-
ventive visits and that time pressures presented barriers
to conducting adequate PPD screening, especially during
preventive visits for families with complex social needs,
“It is just a matter of saying, ‘This is a priority and put it
through the system’, but we haven’t at this point.”
Phase II: Protocol development and pilot testing of
protocol and implementation strategies
At baseline, completed EPDS forms were present in the
EHR for 75% (58/77) of eligible visits, and documenta-
tion of EPDS review was present for 66% (38/58) of
those with completed screens. Following the implemen-
tation of the new protocol, PPD screening was com-
pleted at 86% of the 324 eligible well-child visits that
occurred between October 1 and December 31, 2018. Of
these, 86% (238/278) had documentation that the EPDS
responses had been reviewed. Only 6.5% (18/278) of the
completed screens had a score of 10 or greater (high
likelihood of PPD). Qualitative feedback from pediatric
providers and the Patient and Family Advisory Council
suggested that low rates might be accounted for by cul-
tural differences on how depression is perceived and po-
tentially stigmatized and mothers’ concerns about
drawing the attention of child protective services.
The majority of providers and staff who gave feedback
felt that the bundle of implementation strategies used was
appropriate, but some felt that more education about PPD
and how to use the EPDS would be helpful. One physician
felt that neither the new protocol nor the strategies were
appropriate because she believed that the current screen-
ing processes were adequate and that the workgroup
should focus on being sure providers bill for the screening.
Assessment of acceptability of the implementation strat-
egies showed that most providers felt that the feedback on
screening was effective, but preferred having the feedback
sent by text rather than by e-mail. Some also felt that the
practice’s standard communication processes slowed the
diffusion of information about the new protocol and its
implementation. Although pediatric providers and staff
reported that the process of revising and implementing
the PPD protocol was feasible with the support of the in-
vestigative team, they expressed concerns that the process
might not be feasible without the external facilitation.
Discussion
The failure to systematically implement effective PPD
screening in safety-net pediatric practices in the USA
means that women from lower-income and/or racial and
ethnic minority groups are more likely to develop PPD
and to experience the deleterious effects of untreated
PPD for both themselves and their children. Racial and
ethnic disparities in maternal mortality rates in the USA
[31] and the association of maternal mental health with
these high mortality rates make delivering evidence-
based PPD care to higher-risk women even more of a
priority. Facilitated development and implementation of
a PPD screening protocol in a safety-net practice proved
feasible in this study as evidenced by the increase in the
percentage of women screened and documentation of
plans following screening. The bundle of implementa-
tion strategies tested was largely found to be applicable,
acceptable, and feasible with some adaptations. However,
the unanticipated finding of a much lower-than-
expected percentage of women with positive screens
raised important new questions about the validity of a
commonly used PPD screening tool and how best to de-
ploy the tool in pediatric practices serving lower-income
and racial and ethnic minority families.
The EPDS is one of the most commonly used PPD
screening tools in primary care settings and was found
to have a sensitivity of 86%, specificity of 78%, and posi-
tive predictive value of 73% when it was first developed
[28]. Subsequent studies of its psychometric properties
have found that the EPDS may perform differently in
some patient populations [32–35]. The investigators
who developed the EPDS have cautioned that its psycho-
metric properties should be evaluated for different test-
ing conditions [36], but this is time-consuming, costly,
and often not done. The lower-than-expected percentage
of women with positive screens for depressive symptoms
found in the current study could potentially be explained
by the concerns expressed during the focus groups that
some women may be less comfortable disclosing depres-
sive symptoms to their child’s pediatric provider than
they would be with their own provider if those concerns
are validated. Focus group participants further hypothe-
sized that if some women do in fact feel uncomfortable,
the discomfort might stem from a lack of trust in the
healthcare system, cultural and linguistic factors, and
fear of involvement of child protection service, consist-
ent with theoretical concerns expressed in prior studies
[3, 37, 38]. These findings suggest that increasing the
percentage of women screened for PPD in safety-net
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pediatric practices may be necessary, but not sufficient
to address disparities in PPD care.
In addition to finding low positive screen rates, this
study identified contextual factors in several CFIR do-
mains and at multiple levels that may need to be consid-
ered when implementing interventions to improve PPD
care for women in the populations and practice setting
studied. Some of the factors identified, such as difficul-
ties coordinating care when a patient is not the referring
provider’s patient and the effects of stigma related to
mental health disorders, concur with prior studies [10,
17, 32]. The current study also identified barriers created
by privacy regulations, which pediatric providers felt lim-
ited their capacity to advocate for women who may have
greater challenges navigating the mental healthcare sys-
tem due to language, literacy, transportation, and insur-
ance status barriers. Health policies and practice
structures that address these and other barriers, such as
EHR prompts that require PPD screening results to be
entered before moving to other parts of the EHR, may
help improve the translation of evidence-based PPD care
into practice in this setting.
Limitations of the study include recruitment from one
geographic location since studies in other practices and
other regions might find different contextual barriers to
screening. However, the study was designed to create a
flexible process for protocol development and imple-
mentation that could be adapted in different settings.
Conducting focus groups with postpartum women was
outside of the scope of the study, but this would likely
help to further understand contextual barriers to PPD
screening beyond what we learned from members of the
Patient and Family Advisory Council. We collected
qualitative data for implementation outcomes for this
pilot study, but a systematic mixed-methods assessment
of these outcomes would be of use when scaling up this
study. This study was not designed to test the effective-
ness of individual implementation strategies, but future
studies may compare the effectiveness of different bun-
dles of strategies. Sustainment of changes beyond the
pilot study period was outside of the scope of the study
but will be an important implementation outcome to
measure in future studies. Finally, interventions to im-
prove screening for other high-risk groups of women
(e.g., a prior diagnosis of depression or mothers of multi-
ples, or preterm infants) may require different consider-
ations than those identified in this study.
Conclusions
This study demonstrated the feasibility of developing and
implementing an adaptable protocol for PPD screening in
pediatric practices serving families with lower-income and/
or racial and ethnic minority status using external facilita-
tion and a bundle of implementation strategies selected by
a practice site. However, it also raised some important
questions about how contextual factors at the intersection
of inner setting (e.g., pediatric (vs adult) practice, work-
flows) and outer setting (e.g., low-income and racial/ethnic
minority population needs, child protection service policies)
may reduce the sensitivity of PPD screening instruments
and may require adaptations to how screening instruments
are deployed. Although further study will be needed to bet-
ter understand the effect of these contextual factors, this
study suggests that in-person screening by a trusted person
rather than completion of a paper form before seeing the
pediatric provider may increase the sensitivity of the EPDS.
The study also suggests that PPD screening may be en-
hanced by systems-level changes in practice structures,
such as co-locating obstetric and pediatric care, adapting
workflows to prioritize PPD screening, and engaging all
pediatric healthcare team members in PPD care.
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